Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma

Analytical and Bioanalytical Chemistry

Volumn 396, Issue 2, 2010, Pages 791-798

  Baietto, Lorena ^a   D'Avolio, Antonio ^a   De Rosa, Francesco Giuseppe ^a   Garazzino, Silvia ^a   Michelazzo, Marianna ^a   Ventimiglia, Giusi ^a   Siccardi, Marco ^a   Simiele, Marco ^a   Sciandra, Mauro ^a   Di Perri, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Amikacin; Daptomycin; Gentamicin; HPLC MS; Rifampicin; Therapeutic drug monitoring

Indexed keywords

AMIKACIN; ANALYTICAL PROCEDURE; CLINICAL PHARMACOKINETICS; DAPTOMYCIN; DIRECT INJECTION; DRUG RETENTION; EXTRACTION METHOD; EXTRACTION PROCEDURE; HPLC METHOD; HPLC-MS; HUMAN PLASMAS; INTERNAL STANDARDS; ION PAIRS; LIMITS OF QUANTIFICATION; MASS DETECTION; PROTEIN PRECIPITATION; QUINOXALINES; SAMPLE PREPARATION; THERAPEUTIC DRUG MONITORING; TRIFLUOROACETIC ACIDS;

ACETONITRILE; CHROMATOGRAPHIC ANALYSIS; CHROMATOGRAPHY; DRUG PRODUCTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUIDS; PATIENT MONITORING; PLASMA (HUMAN); PLASMAS; SULFUR COMPOUNDS;

HIGH PRESSURE LIQUID CHROMATOGRAPHY;

AMIKACIN; ANTIINFECTIVE AGENT; DAPTOMYCIN; GENTAMICIN; RIFAMPICIN;

BLOOD; CONFERENCE PAPER; EVALUATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSTRUMENTATION; METHODOLOGY; STATISTICAL PARAMETERS; VALIDATION STUDY;

AMIKACIN; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DAPTOMYCIN; GENTAMICINS; HUMANS; LIMIT OF DETECTION; RIFAMPIN;

EID: 76849107521     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-009-3263-1     Document Type: Conference Paper

References (45)

1. Wiedemann B (2006) Test results: characterising the antimicrobial activity of daptomycin. Clin Microbiol Infect 6
2. JA Silverman NG Perlmutter HM Shapiro 2003 Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus Antimicrob Agents Chemother 47 2538 2544 10.1128/AAC.47.8.2538-2544.2003 1:CAS:528:DC%2BD3sXlvFClsrw%3D (Pubitemid 36919456)
3. KL Tedesco MJ Rybak 2004 Daptomycin Pharmacotherapy 24 41 57 10.1592/phco.24.1.41.34802 1:CAS:528:DC%2BD2cXht1Snu78%3D (Pubitemid 38056251)
4. MJ Rybak E Hershberger T Moldovan RG Grucz 2000 In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and -resistant strains Antimicrob Agents Chemother 44 1062 1066 10.1128/AAC.44.4.1062-1066.2000 1:CAS:528:DC%2BD3cXitFOksrs%3D (Pubitemid 30165292)
5. HS Sader JM Streit TR Fritsche RN Jones 2004 Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide Diagn Microbiol Infect Dis 50 201 204 10.1016/j.diagmicrobio.2004.07.002 1:CAS:528:DC%2BD2cXpslGgtbw%3D (Pubitemid 39487294)
6. JM Streit RN Jones HS Sader 2004 Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms J Antimicrob Chemother 53 669 674 10.1093/jac/dkh143 1:CAS:528:DC%2BD2cXisF2lsrk%3D (Pubitemid 38499788)
7. K Credito G Lin PC Appelbaum 2007 Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology Antimicrob Agents Chemother 51 1504 1507 10.1128/AAC.01455-06 1:CAS:528:DC%2BD2sXktlOjuro%3D (Pubitemid 46586838)
8. D Carrier M Bou Khalil A Kealey 1998 Modulation of phospholipase A2 activity by aminoglycosides and daptomycin: a Fourier transform infrared spectroscopic study Biochemistry 37 7589 7597 10.1021/bi971793d 1:CAS:528:DyaK1cXislGgtb0%3D (Pubitemid 28235243)
9. G Pankey D Ashcraft N Patel 2005 In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin Antimicrob Agents Chemother 49 5166 5168 10.1128/AAC.49.12.5166-5168.2005 1:CAS:528:DC%2BD2MXhtlSqsrvO (Pubitemid 41778943)
10. BH Dvorchik D Brazier MF DeBruin RD Arbeit 2003 Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects Antimicrob Agents Chemother 47 1318 1323 10.1128/AAC.47.4.1318-1323.2003 1:CAS:528:DC%2BD3sXivVSmsr8%3D (Pubitemid 36368592)
11. J Martens-Lobenhoffer JT Kielstein C Oye SM Bode-Boger 2008 Validated high performance liquid chromatography-UV detection method for the determination of daptomycin in human plasma J Chromatogr 875 546 550 10.1016/j.jchromb.2008. 09.019 1:CAS:528:DC%2BD1cXhtlGhur3O
12. CM Tobin JM Darville AM Lovering AP Macgowan 2008 An HPLC assay for daptomycin in serum J Antimicrob Chemother 62 1462 1463 10.1093/jac/dkn414 1:CAS:528:DC%2BD1cXhtl2gs7rI
13. WE Rose MJ Rybak GW Kaatz 2007 Evaluation of daptomycin treatment of staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies J Antimicrob Chemother 60 334 340 10.1093/jac/dkm170 1:CAS:528:DC%2BD2sXos12mt7g%3D (Pubitemid 47243883)
14. HJ Schaad M Bento DP Lew P Vaudaux 2006 Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection BMC Infect Dis 6 74 10.1186/1471-2334-6-74
15. EA Papp CA Knupp RH Barbhaiya 1992 High-performance liquid chromatographic assays for the quantification of amikacin in human plasma and urine J Chromatogr 574 93 99 10.1016/0378-4347(92)80102-V 1:CAS:528: DyaK38XpvVyitA%3D%3D
16. S Nicoli P Santi 2006 Assay of amikacin in the skin by high-performance liquid chromatography J Pharm Biomed Anal 41 994 997 10.1016/j.jpba.2005.12.029 1:CAS:528:DC%2BD28Xks1Cju7o%3D
17. JM Serrano M Silva 2006 Determination of amikacin in body fluid by high-performance liquid-chromatography with chemiluminescence detection J Chromatogr 843 20 24 10.1016/j.jchromb.2006.05.016 1:CAS:528:DC%2BD28XhtVyktrzI (Pubitemid 44540266)
18. B Wichert H Schreier H Derendorf 1991 Sensitive liquid chromatography assay for the determination of amikacin in human plasma J Pharm Biomed Anal 9 251 254 10.1016/0731-7085(91)80154-2 1:CAS:528:DyaK3MXkt1Wms7c%3D
19. LT Wong AR Beaubien AP Pakuts 1982 Determination of amikacin in microlitre quantities of biological fluids by high-performance liquid chromatography using 1-fluoro-2, 4-dinitrobenzene derivatization J Chromatogr 231 145 154 10.1016/S0378-4347(00)80518-6 1:CAS:528:DyaL38XltVektLY%3D
20. N Isoherranen S Soback 2000 Determination of gentamicins C(1), C(1a), and C(2) in plasma and urine by HPLC Clin Chem 46 837 842 1:CAS:528: DC%2BD3cXkt1ejtbs%3D
21. C Lecaroz MA Campanero C Gamazo MJ Blanco-Prieto 2006 Determination of gentamicin in different matrices by a new sensitive high-performance liquid chromatography-mass spectrometric method J Antimicrob Chemother 58 557 563 10.1093/jac/dkl258 1:CAS:528:DC%2BD28Xotl2ltL0%3D (Pubitemid 44288119)
22. A Yusuf S Al-Rawithi D Raines H Frayha TA Toonsi I Al-Mohsen E-Y A 1999 Simplified high-performance liquid chromatographic method for the determination of gentamicin sulfate in a microsample of plasma: comparison with fluorescence polarization immunoassay Ther Drug Monit 21 647 652 10.1097/00007691-199912000- 00012 1:CAS:528:DC%2BD3cXktFGq
23. AL Allanson MM Cotton JN Tettey AC Boyter 2007 Determination of rifampicin in human plasma and blood spots by high performance liquid chromatography with UV detection: a potential method for therapeutic drug monitoring J Pharm Biomed Anal 44 963 969 10.1016/j.jpba.2007.04.007 1:CAS:528:DC%2BD2sXot1yhsbs%3D (Pubitemid 47096856)
24. M Boffito J Tija HE Reynolds PG Hoggard S Bonora G Di Perri DJ Back 2002 Simultaneous determination of rifampicin and efavirenz in plasma Ther Drug Monit 24 670 674 10.1097/00007691-200210000-00015 1:CAS:528:DC%2BD38XnsVWmsb0%3D
25. RC Hartkoorn S Khoo DJ Back JF Tjia CJ Waitt M Chaponda, et al. 2007 A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin J Chromatogr 857 76 82 10.1016/j.jchromb.2007.07.005 1:CAS:528:DC%2BD2sXhtVWmsLvL (Pubitemid 47371222)
26. HM Ziglam DR Baldwin I Daniels JM Andrew RG Finch 2002 Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy J Antimicrob Chemother 50 1011 1015 10.1093/jac/dkf214 1:CAS:528:DC%2BD38XptlOis7c%3D (Pubitemid 36032825)
27. FDA (2001) Guidance for industry: bioanalytical method validation. ( http://fdagov/cder/guidance/4252fnlpdf )
28. PJ Taylor 2005 Clin Biochem 38 667 73 10.1016/j.clinbiochem.2004.11.007 (Pubitemid 40342863)
29. VG Fowler Jr HW Boucher GR Corey E Abrutyn AW Karchmer ME Rupp, et al. 2006 Daptomycin versus standard therapy for bacteremia and endocarditis caused by staphylococcus aureus N Engl J Med 355 653 665 10.1056/NEJMoa053783 1:CAS:528:DC%2BD28Xot12mt7k%3D (Pubitemid 44244536)
30. RA Seaton 2008 Daptomycin: rationale and role in the management of skin and soft tissue infections J Antimicrob Chemother 62 Suppl 3 iii15 23 10.1093/jac/dkn368 1:CAS:528:DC%2BD1cXhsV2mu7nO
31. RD Arbeit D Maki FP Tally E Campanaro BI Eisenstein 2004 The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections Clin Infect Dis 38 1673 1681 10.1086/420818 1:CAS:528: DC%2BD2cXlvFSjsrg%3D (Pubitemid 38781657)
32. R Cha RG Grucz Jr MJ Rybak 2003 Daptomycin dose-effect relationship against resistant gram-positive organisms Antimicrob Agents Chemother 47 1598 1603 10.1128/AAC.47.5.1598-1603.2003 1:CAS:528:DC%2BD3sXjslGhtLs%3D (Pubitemid 36548543)
33. N Safdar D Andes WA Craig 2004 In vivo pharmacodynamic activity of daptomycin Antimicrob Agents Chemother 48 63 8 10.1128/AAC.48.1.63-68.2004 1:CAS:528:DC%2BD2cXlsVKktg%3D%3D (Pubitemid 38040177)
34. FP Tally M Zeckel MM Wasilewski C Carini CL Berman GL Drusano FB Oleson Jr 1999 Daptomycin: a novel agent for Gram-positive infections Expert Opin Investig Drugs 8 1223 1238 10.1517/13543784.8.8.1223 1:CAS:528: DyaK1MXltFGgsrY%3D (Pubitemid 29410579)
35. CC Wagner I Steiner M Zeitlinger 2009 Daptomycin elimination by CVVH in vitro: evaluation of factors influencing sieving and membrane adsorption Int J Clin Pharmacol Ther 47 178 186 1:CAS:528:DC%2BD1MXkslGnsb0%3D
36. JF Ovalles MR del Brunetto M Gallignani 2005 A new method for the analysis of amikacin using 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC) derivatization and high-performance liquid chromatography with UV-detection J Pharm Biomed Anal 39 294 298 10.1016/j.jpba.2005.02.030 1:CAS:528: DC%2BD2MXntVGit7w%3D (Pubitemid 41112150)
37. KR Lung KR Kassal JS Green PK Hovsepian 1998 Catalytic precolumn derivatization of amikacin J Pharm Biomed Anal 16 905 910 10.1016/S0731-7085(97) 00136-2 1:CAS:528:DyaK1cXhsVKgsr8%3D (Pubitemid 28097419)
38. P Gambardella R Punziano M Gionti C Guadalupi G Mancini A Mangia 1985 Quantitative determination and separation of analogues of aminoglycoside antibiotics by high-performance liquid chromatography J Chromatogr 348 229 240 10.1016/S0021-9673(01)92457-4 1:CAS:528:DyaL28XjvFygsQ%3D%3D
39. L Essers 1984 An automated high-performance liquid chromatographic method for the determination of aminoglycosides in serum using pre-column sample clean-up and derivatization J Chromatogr 305 345 352 10.1016/S0378-4347(00) 83348-4 1:CAS:528:DyaL2cXhtFCntr0%3D
40. M Benvenuto DP Benziger S Yankelev G Vigliani 2006 Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers Antimicrob Agents Chemother 50 3245 3249 10.1128/AAC.00247-06 1:CAS:528:DC%2BD28XhtVylsbrE (Pubitemid 44527494)
41. JF Mohr 3rd L Ostrosky-Zeichner DJ Wainright DH Parks TC Hollenbeck CD Ericsson 2008 Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury Antimicrob Agents Chemother 52 1891 1893 10.1128/AAC.01321-07 1:CAS:528:DC%2BD1cXls1ais7k%3D (Pubitemid 351614698)
42. C Bartal A Danon F Schlaeffer K Reisenberg M Alkan R Smoliakov, et al. 2003 Pharmacokinetic dosing of aminoglycosides: a controlled trial Am J Med 114 194 198 10.1016/S0002-9343(02)01476-6 1:CAS:528:DC%2BD3sXhvFeqtbk%3D (Pubitemid 36294004)
43. R Ruslami HM Nijland B Alisjahbana I Parwati R van Crevel RE Aarnoutse 2007 Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients Antimicrob Agents Chemother 51 2546 2551 10.1128/AAC.01550-06 1:CAS:528:DC%2BD2sXnsVajsrk%3D (Pubitemid 47047335)
44. R Ruslami H Nijland R Aarnoutse B Alisjahbana AY Soeroto S Ewalds R van Crevel 2006 Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis Antimicrob Agents Chemother 50 822 823 10.1128/AAC.50.2.822-823.2006 1:CAS:528:DC%2BD28XhsFensrc%3D (Pubitemid 43191013)
45. R van Crevel B Alisjahbana WC de Lange F Borst H Danusantoso JW van der Meer, et al. 2002 Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia Int J Tuberc Lung Dis 6 497 502